Over the lifetime of the Midas List, IT investors have beat out life science VCs for a number of reasons, including contrasted market dynamics, significant capital and time requirements, heavy life science regulations, and smaller public offerings for some life science companies. But this year, the winds may be shifting.
Over the lifetime of the Midas List, IT investors have beat out life science VCs for a number of reasons, including contrasted market dynamics, significant capital and time requirements, heavy life science regulations, and smaller public offerings for some life science companies. But this year, the winds may be shifting.
Share this Article
Recommended